News By Location

Researchers at Los Alamos National Laboraotry are creating double-pane solar windows that generate electricity with greater efficiency and also create shading and insulation. It's all made possible by a new window architecture which utilizes two different layers of low-cost quantum dots tuned to absorb different parts of the solar spectrum. The approach complements existing photovoltaic technology by adding high-efficiency sunlight collectors to existing solar panels or integrating them as semitransparent windows into a building's architecture.

Research at Sandia National Laboratories has identified a major obstacle to advancing solid-state lithium-ion battery performance in small electronics: the flow of lithium ions across battery interfaces.

A printing process uses natural forces to grow an inexpensive catalyst to replace platinum to lower the cost of hydrogen-powered cars.

New supercomputer simulations have revealed the role of transport proteins called efflux pumps in creating drug-resistance in bacteria, research that could lead to improving the drugs' effectiveness against life-threatening diseases and restoring the efficacy of defunct antibiotics.

Just in time for World AIDS Day (Dec. 1) international partners are announcing the first efficacy study for an investigational HIV-1-preventive 'mosaic' vaccine. Janssen Pharmaceutical Companies of Johnson & Johnson are joining forces with The Bill & Melinda Gates Foundation and National Institutes of Health on this study, and they have enlisted the aid of top researchers worldwide to conduct the trial.

Sandia researchers have created an alternative reality to mislead hackers, damaging the credibility of any information collected by cyberintruders.

Prominent researchers Angel E. Garcia and Laura Smilowitz of Los Alamos National Laboratory have been named Fellows of the American Association for the Advancement of Science (AAAS). Election as a Fellow of AAAS is an honor bestowed upon Association members by their peers.

Gene editing holds great promise for 'deleting' diseases from human bodies. Sandia National Laboratories is working to make this technology safer and to ensure that one day it can be delivered into humans without triggering adverse immune system reactions or causing other undesirable side effects.